Nengwen Ke

Prof. Nengwen Ke

Department of Pancreatic Surgery, West China Hospital, Chengdu, Sichuan, China
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2025 in Cancer Discovery
Verified
Journal Article
Closed access
WXWenyan Xie
Wenyan Xie
XYXin Yu
Xin Yu
QYQingxin Yang
Qingxin Yang
NKNengwen Ke
Nengwen Ke
PWPing Wang
Ping Wang
HJHong Jiang
Hong Jiang
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a fibrotic, stiff tumor microenvironment in which tumor-associated macrophages (TAM) drive extracellular matrix remodeling, progression, and immune evasion. The contribution of mechanical cues to monocyte differentiation into TAMs remains largely unexplored. In this study, we show that mechanical force is required for monocyte-to-macrophage differentiation. PYK2, as an immunomechanical checkpoint, de facto governs this differentiation process. We demonstrated that PYK2 senses mechanical signals via PIEZO1 and integrins, triggering F-actin polymerization and translocating to the nucleus to regulate mechanotransduction and differentiation genes (e.g., ACTR3, RELA). Targeted deletion of Ptk2b, which encodes PYK2 impairs the differentiation and polarization of monocyte-derived macrophages, reshapes the PDAC microenvironment, and enhances the efficacy of anti–PD-1 immunotherapy. These findings underscore the critical role of mechanical cues in monocyte differentiation and suggest that targeting PYK2 is a promising strategy to modulate TAM function and improve immunotherapy outcomes in patients with PDAC. Significance: This study identifies PYK2 as an immunomechanical checkpoint that drives monocyte-to-macrophage differentiation in PDAC via PIEZO1/integrin-mediated mechanical cues. Targeted deletion of Ptk2b (PYK2) reshapes the PDAC microenvironment and enhances the efficacy of anti–PD-1 immunotherapy, suggesting PYK2 as a promising therapeutic target to overcome immunotherapy resistance.

1 July 2016 in Immunobiology
Verified
Journal Article
Closed access
NKNengwen Ke
Nengwen Ke
ASAnping Su
Anping Su
WHWei Huang
Wei Huang
Peter SzatmaryPeter Szatmary
Peter Szatmary
ZZZhaoda Zhang
Zhaoda Zhang

7 June 2023 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
RGRuiman Geng
Ruiman Geng
NKNengwen Ke
Nengwen Ke
ZWZiyao Wang
Ziyao Wang
YMYu Mou
Yu Mou
BXBin Xiang
Bin Xiang
JLji liu
ji liu

12 December 2022 in International Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
ZWZiyao Wang
Ziyao Wang
CCChen Chen
Chen Chen
YSYingzhen Su
Yingzhen Su
NKNengwen Ke
Nengwen Ke
T‑cell/transmembrane immunoglobulin and mucin domain containing 4 (TIM‑4) is a phosphatidylserine receptor that is mainly expressed on antigen‑presenting cells and is involved in the recognition and efferocytosis of apoptotic cells. TIM‑4 has been found to be expressed in immune cells such as natural killer T, B and mast cells and to participate in multiple aspects of immune regulation, suggesting that TIM‑4 may be involved in a variety of immune‑related diseases. Recent studies have confirmed that TIM‑4 is also abnormally expressed in a variety of malignant tumor cells and is closely associated with the occurrence and development of tumors and the tumor immune microenvironment. The present study aimed to describe the expression and functional characteristics of TIM‑4 in detail and to comprehensively discuss its role in pathophysiological processes such as infection, allergy, metabolism, autoimmunity and tumor immunity. The current review provided a comprehensive understanding of the functions and characteristics of TIM‑4, as well as novel ideas for the diagnosis and treatment of diseases.

8 March 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
YMYu Mou
Yu Mou
ZWZi-Yao Wang
Zi-Yao Wang
CTChun-Lu Tan
Chun-Lu Tan
YCYong-Hua Chen
Yong-Hua Chen
GCGuanhua Chen Chunlu Tan Xubao Liu Yonghua Chen
Guanhua Chen Chunlu Tan Xubao Liu Yonghua Chen
NKNengwen Ke
Nengwen Ke
Background: Liver metastases (LMs) are common in advanced pancreatic neuroendocrine tumor (PNET) patients. Currently, the benefit of primary tumor resection (PTR) in the setting of PNET patients with liver metastases is still controversial in several guidelines.Methods: Data were extracted from the Surveillance, Epidemiology and End Results (SEER) database to evaluate this issue. The main index of interest in our study was overall survival time.Results: Information on 536 PNET patients with liver metastases from the SEER database was identified. A total of 214 patients (PTR group) received primary tumor resection, and more than half of them (132 patients) had synchronous LM resection. The other 322 PNET patients (non-PTR group) with liver metastases did not receive primary tumor resection. A significant survival benefit was gained from PTR when compared with non-PTR patients, both in OS (72.93 ± 2.7 vs. 36.80 ± 2.22 months) and 3- or 5-year survival rates (75.1% vs. 28.9% and 67.9% vs. 22.3%, respectively). No difference was found between PTR alone and PTR with synchronous LM resection. From univariate and multivariate analyses, younger age (<65 years) and good or moderate tumor differentiation may be more important when considering primary tumor resection. However, we found that all grades of tumor differentiation could result in a better overall survival time after primary tumor resection.Conclusion: Our study suggested that primary tumor resection in pancreatic neuroendocrine patients with liver metastases could result in a longer survival time. Primary tumor resection with synchronous liver metastasis resection was not related to a better survival benefit. This treatment strategy may routinely be taken into consideration in these patients.

20 March 2023 in Cancer Medicine
Verified
Journal Article
Open access
XSXiao‐Ding Shen
Xiao‐Ding Shen
XWXing Wang
Xing Wang
ZZZhen‐Jiang Zheng
Zhen‐Jiang Zheng
YCYong‐Hua Chen
Yong‐Hua Chen
CTChunlu Tan
Chunlu Tan
NKNengwen Ke
Nengwen Ke
Objectives: Both cachexia and sarcopenia have been considered adverse predictors for prognosis in patients with pancreatic cancer; although sarcopenia and cachexia share some similarities, they are still defined as distinct nutritional conditions. We aimed to explore the differential impacts of sarcopenia and cachexia on prognosis for pancreatic ductal adenocarcinoma (PDAC) patients following radical excision.Methods: From January 2015 to May 2022, 614 patients undergoing surgery for PDAC were retrospectively included. Sarcopenia was defined as the L3 total skeletal muscle index below 52.4 cm2/m2 (men) and 38.5 cm2/m2 (women). Cachexia was classified according to the following criteria: involuntary weight loss >5% over the past 6 months, or weight loss >2% and BMI 2% and sarcopenia.Results: Of the 614 patients included in the analysis, 62% and 48% were diagnosed with sarcopenia and cachexia, respectively. Kaplan–Meier analysis showed that sarcopenia and/or cachexia were significantly associated with worse overall survival (OS) rather than worse recurrence‐free survival (RFS). Moreover, Cox regression analysis revealed that cachexia rather than sarcopenia was an adverse factor for OS in all PDAC patients. For poorly differentiated PDAC, both cachexia and sarcopenia were significantly associated with shorter OS. However, for moderately/well‐differentiated PADC, cachexia was an independent factor for adverse OS, but not sarcopenia.Conclusions: Sarcopenia and cachexia have different effects on OS for PDAC patients undergoing radical excision. This difference may provide some important information for preoperative management.